MDCLF (Medincell) 1-Year Sortino Ratio: 331.63 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCLF Medincell SA MDCLF
77 GF Score
Price $34.39
GF Value $27.51
! 5 Warning Signs
View Full Analysis

What is Medincell 1-Year Sortino Ratio?

Medincell MDCLF +393.00% 77 1-Year Sortino Ratio is 331.63 as of Jul. 14, 2026. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review.

The 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past year. As of today (2026-07-14), Medincell's 1-Year Sortino Ratio is 331.63.

Medincell  (OTCPK:MDCLF) 1-Year Sortino Ratio Explanation

The 1-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by the standard deviation of negative returns over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.

Medincell 1-Year Sortino Ratio Related Terms

MDCLF vs VRTX, REGN, ALNY: 1-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Medincell's 1-Year Sortino Ratio, along with its competitors' market caps and 1-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell 1-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's 1-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Medincell's 1-Year Sortino Ratio falls into.


MDCLF
77GF Score
Medincell SA MDCLF
1-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell 1-Year Sortino Ratio Calculation

The 1-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio over the past year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 1-Year Sortino Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the downside risks over one year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Frequently Asked Questions Learn more about 1-Year Sortino Ratio →
What does a 1-Year Sortino Ratio of 331.63 mean?
Medincell (MDCLF) has a 1-Year Sortino Ratio of 331.63 as of Jul. 14, 2026. 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk. View historical data for Medincell and its competitors.
Is Medincell's 1-Year Sortino Ratio too high?
Medincell's current 1-Year Sortino Ratio is 331.63. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's 1-Year Sortino Ratio compare to VRTX and REGN?
Medincell's 1-Year Sortino Ratio of 331.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sortino Ratio for a Biotechnology company?
A good 1-Year Sortino Ratio depends on the Biotechnology industry context. However, 1-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sortino Ratio mean?
A high 1-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk. View historical data for Medincell and its competitors. Medincell's current 1-Year Sortino Ratio is 331.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current 1-Year Sortino Ratio of 331.63. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current 1-Year Sortino Ratio is 331.63. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sortino Ratio calculated?
1-Year Sortino Ratio is calculated from a company's financial statements. For Medincell (MDCLF), the current 1-Year Sortino Ratio is 331.63 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (MDCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.

Key valuation signals for MDCLF:

  • 1-Year Sortino Ratio: 331.63
  • GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for MDCLF

1-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.39
Price
$27.51
GF Value